Evidence map›Paper›PMID 34606255›Full record

ArticleAnalytical chemistry2021

PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors.

He Zhu, Scott B Ficarro, William M Alexander, Laura E Fleming, Guillaume Adelmant, Tinghu Zhang, Matthew Willetts, Jens Decker, Sven Brehmer, Michael Krause and 5 more

Abstract read
In one paragraph

Article in Analytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

He ZhuDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID 0000-0002-9925-2640
Scott B FicarroDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
William M AlexanderDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Laura E FlemingDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Guillaume AdelmantDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Tinghu ZhangDepartment of Chemical & Systems Biology and ChEM-H, Stanford University School of Medicine, Stanford, California 94305, United States.
Matthew WillettsBruker Daltonics Inc, Billerica, Massachusetts 01821, United States.
Jens DeckerBruker Daltonics GmbH & Co. KG, Bremen 28359, Germany.
Sven BrehmerBruker Daltonics GmbH & Co. KG, Bremen 28359, Germany.
Michael KrauseBruker Daltonics GmbH & Co. KG, Bremen 28359, Germany.
Michael P EastDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Nathanael S GrayDepartment of Chemical & Systems Biology and ChEM-H, Stanford University School of Medicine, Stanford, California 94305, United States.ORCID 0000-0001-5354-7403
Gary L JohnsonDepartment of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Gary KruppaBruker S.R.O., District Brno-City 61900, Czech Republic.
Jarrod A MartoDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID 0000-0003-2086-1134

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
Novel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5M
Tools for DUB Drug DiscoveryR21CA247671 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2020 to 2021
$648k
NCI NIH HHS R01 CA233800NCI NIH HHS R21 CA247671NIDDK NIH HHS U24 DK116204
6 · The paper itself

Abstract

Parallel reaction monitoring (PRM) has emerged as a popular approach for targeted protein quantification. With high ion utilization efficiency and first-in-class acquisition speed, the timsTOF Pro provides a powerful platform for PRM analysis. However, sporadic chromatographic drift in peptide retention time represents a fundamental limitation for the reproducible multiplexing of targets across PRM acquisitions. Here, we present PRM-LIVE, an extensible, Python-based acquisition engine for the timsTOF Pro, which dynamically adjusts detection windows for reproducible target scheduling. In this initial implementation, we used iRT peptides as retention time standards and demonstrated reproducible detection and quantification of 1857 tryptic peptides from the cell lysate in a 60 min PRM-LIVE acquisition. As an application in functional proteomics, we use PRM-LIVE in an activity-based protein profiling platform to assess binding selectivity of small-molecule inhibitors against 220 endogenous human kinases.

Indexed as

Ion Mobility SpectrometryProteomicsHumansMass SpectrometryPeptidesProteinsPeptidesProteins

Identifiers

PMID34606255
PMCPMC9297317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.